Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
Public ClinicalTrials.gov record NCT07729137. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 2 Study of EO2002 in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction (EMERALD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety and effectiveness of a single injection of EO2002 at one of two dose levels (150,000 or 500,000 magnetic human corneal endothelial cells \[mHCECs\]), compared with a placebo injection, in participants with corneal edema caused by corneal endothelial dysfunction.
Study identification
- NCT ID
- NCT07729137
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 121 participants
Conditions and interventions
Conditions
- Corneal Edema
- Fuchs
- Fuchs Dystrophy
- Fuchs' Endothelial Dystrophy
- Endothelial Corneal Dystrophy
- Corneal Endothelial Decompensation
- Corneal Endothelial Cell Loss
- Corneal Endothelial Disorder
- Corneal Endothelial Dystrophy 1
- Endothelial Cell Loss, Corneal
- Pseudophakic Bullous Keratopathy
- Pseudophakic Bullous Keratopathy (PBK)
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2026 (Estimated)
- Primary completion
- Aug 2027 (Estimated)
- Completion
- Feb 2028 (Estimated)
- Last update posted
- Oct 9, 2026
2026 – 2028
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Torrance, California | Torrance | California | 90505 | Not yet recruiting |
| Largo, Florida | Largo | Florida | 33770 | Not yet recruiting |
| Atlanta, Georgia | Atlanta | Georgia | 30339 | Not yet recruiting |
| Chicago, Illinois | Chicago | Illinois | 60612 | Not yet recruiting |
| Carmel, Indiana | Carmel | Indiana | 46032 | Recruiting |
| Overland Park, Kansas | Overland Park | Kansas | 66204 | Not yet recruiting |
| Minnetonka, Minnesota | Minnetonka | Minnesota | 55305 | Not yet recruiting |
| Kansas City, Missouri | Kansas City | Missouri | 64133 | Not yet recruiting |
| Garden City, NY | Garden City | New York | 11530 | Not yet recruiting |
| Salt Lake City, Utah | Salt Lake City | Utah | 84107 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07729137, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07729137 live on ClinicalTrials.gov.